10x Genomics (0A88) Share Forecast & Price Target

6 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0A88 Analyst Ratings

Moderate Buy

6 Buy

7 Hold

0 Sell

Based on 13 analysts giving stock ratings to

10x

Genomics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0A88 Stock 12 Month Forecast

Average Price Target

$50.36

▲(9.70% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for 10x Genomics in the last 3 months. The average price target is $50.36 with a high forecast of $65.00 and a low forecast of $40.00. The average price target represents a 9.70% change from the last price of $45.91.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","66":"$66","24.75":"$24.8","38.5":"$38.5","52.25":"$52.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$65.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50.36363636363637,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$50.36</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$40.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,24.75,38.5,52.25,66],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,48.01,49.316923076923075,50.62384615384615,51.93076923076923,53.237692307692306,54.54461538461538,55.85153846153846,57.15846153846154,58.465384615384615,59.77230769230769,61.07923076923077,62.386153846153846,63.69307692307692,{"y":65,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,48.01,48.19104895104895,48.3720979020979,48.55314685314685,48.73419580419581,48.91524475524476,49.09629370629371,49.27734265734266,49.45839160839161,49.63944055944056,49.820489510489516,50.001538461538466,50.18258741258742,{"y":50.36363636363637,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,48.01,47.393846153846155,46.777692307692305,46.16153846153846,45.54538461538461,44.92923076923077,44.31307692307692,43.69692307692308,43.08076923076923,42.464615384615385,41.848461538461535,41.23230769230769,40.61615384615384,{"y":40,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.035,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.124,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.1,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.65,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.26,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.33,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.01,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.56,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.8,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.59,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.18,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.65,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.01,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$65.00

Average Price Target$50.36

Lowest Price Target$40.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Unknown Analyst

Stephens

Not Ranked

Stephens

$65

Buy

41.58%

Upside

Reiterated

08/12/26

10x Genomics (TXG) Gets a Buy from Stephens

Daniel Arias

Stifel Nicolaus

$50

Buy

8.91%

Upside

Reiterated

08/11/26

10x Genomics (TXG) Receives a Buy from Stifel Nicolaus

David Westenberg

Piper Sandler

$42→$47

Hold

2.37%

Upside

Reiterated

08/10/26

Piper Sandler Keeps Their Hold Rating on 10x Genomics (TXG)

Kyle Mikson CFA

Canaccord Genuity

$50→$60

Buy

30.69%

Upside

Reiterated

08/10/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Casey Woodring

J.P. Morgan

$38→$50

Hold

8.91%

Upside

Reiterated

08/10/26

J.P. Morgan Remains a Hold on 10x Genomics (TXG)

Kallum Titchmarsh

Morgan Stanley

$40

Hold

-12.87%

Downside

Assigned

08/10/26

Analysts Offer Insights on Healthcare Companies: Zoetis (NYSE: ZTS), GoodRx Holdings (NASDAQ: GDRX) and 10x Genomics (NASDAQ: TXG)

Matt Larew

William Blair

―

Buy

―

Reiterated

08/07/26

Analysts Offer Insights on Healthcare Companies: Verrica Pharmaceuticals (NASDAQ: VRCA) and 10x Genomics (NASDAQ: TXG)

Tycho Peterson

Jefferies

$53

Buy

15.44%

Upside

Reiterated

08/07/26

Analysts Are Bullish on These Healthcare Stocks: Becton Dickinson (BDX), 10x Genomics (TXG)

Michael Ryskin

Bank of America Securities

―

Hold

―

Reiterated

08/07/26

Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (NASDAQ: ARVN), 10x Genomics (NASDAQ: TXG) and Teleflex (NYSE: TFX)

‏Brendan Digan‏

Citi

$45→$50

Hold

8.91%

Upside

Reiterated

08/07/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Haemonetics (NYSE: HAE), 10x Genomics (NASDAQ: TXG) and Scholar Rock Holding (NASDAQ: SRRK)

Luke Sergott

Barclays

$40→$52

Buy

13.27%

Upside

Reiterated

08/06/26

Puneet Souda

Leerink Partners

$23→$40

Hold

-12.87%

Downside

Reiterated

07/17/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: 10x Genomics (NASDAQ: TXG), Elevance Health (NYSE: ELV) and Johnson & Johnson (NYSE: JNJ)

Daniel Brennan

TD Cowen

$25→$47

Hold

2.37%

Upside

Reiterated

07/15/26

10x Genomics price target raised to $47 from $25 at TD Cowen10x Genomics price target raised to $47 from $25 at TD Cowen

Justin Bowers

Deutsche Bank

$17→$23

Hold

-49.90%

Downside

Reiterated

05/08/26

10x Genomics price target raised to $23 from $17 at Deutsche Bank10x Genomics price target raised to $23 from $17 at Deutsche Bank

Dan Leonard

RBC Capital

$14→$20

Hold

-56.44%

Downside

Reiterated

02/19/26

UBS Reaffirms Their Hold Rating on 10x Genomics (TXG)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Unknown Analyst

Stephens

Not Ranked

Stephens

$65

Buy

41.58%

Upside

Reiterated

08/12/26

10x Genomics (TXG) Gets a Buy from Stephens

Daniel Arias

Stifel Nicolaus

$50

Buy

8.91%

Upside

Reiterated

08/11/26

10x Genomics (TXG) Receives a Buy from Stifel Nicolaus

David Westenberg

Piper Sandler

$42→$47

Hold

2.37%

Upside

Reiterated

08/10/26

Piper Sandler Keeps Their Hold Rating on 10x Genomics (TXG)

Kyle Mikson CFA

Canaccord Genuity

$50→$60

Buy

30.69%

Upside

Reiterated

08/10/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Casey Woodring

J.P. Morgan

$38→$50

Hold

8.91%

Upside

Reiterated

08/10/26

J.P. Morgan Remains a Hold on 10x Genomics (TXG)

Kallum Titchmarsh

Morgan Stanley

$40

Hold

-12.87%

Downside

Assigned

08/10/26

Analysts Offer Insights on Healthcare Companies: Zoetis (NYSE: ZTS), GoodRx Holdings (NASDAQ: GDRX) and 10x Genomics (NASDAQ: TXG)

Matt Larew

William Blair

―

Buy

―

Reiterated

08/07/26

Analysts Offer Insights on Healthcare Companies: Verrica Pharmaceuticals (NASDAQ: VRCA) and 10x Genomics (NASDAQ: TXG)

Tycho Peterson

Jefferies

$53

Buy

15.44%

Upside

Reiterated

08/07/26

Analysts Are Bullish on These Healthcare Stocks: Becton Dickinson (BDX), 10x Genomics (TXG)

Michael Ryskin

Bank of America Securities

―

Hold

―

Reiterated

08/07/26

Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (NASDAQ: ARVN), 10x Genomics (NASDAQ: TXG) and Teleflex (NYSE: TFX)

‏Brendan Digan‏

Citi

$45→$50

Hold

8.91%

Upside

Reiterated

08/07/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Haemonetics (NYSE: HAE), 10x Genomics (NASDAQ: TXG) and Scholar Rock Holding (NASDAQ: SRRK)

Luke Sergott

Barclays

$40→$52

Buy

13.27%

Upside

Reiterated

08/06/26

Puneet Souda

Leerink Partners

$23→$40

Hold

-12.87%

Downside

Reiterated

07/17/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: 10x Genomics (NASDAQ: TXG), Elevance Health (NYSE: ELV) and Johnson & Johnson (NYSE: JNJ)

Daniel Brennan

TD Cowen

$25→$47

Hold

2.37%

Upside

Reiterated

07/15/26

10x Genomics price target raised to $47 from $25 at TD Cowen10x Genomics price target raised to $47 from $25 at TD Cowen

Justin Bowers

Deutsche Bank

$17→$23

Hold

-49.90%

Downside

Reiterated

05/08/26

10x Genomics price target raised to $23 from $17 at Deutsche Bank10x Genomics price target raised to $23 from $17 at Deutsche Bank

Dan Leonard

RBC Capital

$14→$20

Hold

-56.44%

Downside

Reiterated

02/19/26

UBS Reaffirms Their Hold Rating on 10x Genomics (TXG)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ODTXOdyssey Therapeutics, Inc.

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

GPCRStructure Therapeutics, Inc. Sponsored ADR

AMLXAmylyx Pharmaceuticals Inc

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering 10x Genomics

3 Months

Kyle Mikson CFACanaccord Genuity

Success Rate

16/27 ratings generated profit

Average Return

+13.68%

Copying Kyle Mikson CFA's trades and holding each position for 3 Months would result in 59.26% of your transactions generating a profit, with an average return of +13.68% per trade.

1 Year

Kyle Mikson CFACanaccord Genuity

Success Rate

15/27 ratings generated profit

Average Return

+82.42%

Copying Kyle Mikson CFA's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +82.42% per trade.

2 Years

Kyle Mikson CFACanaccord Genuity

Success Rate

18/27 ratings generated profit

Average Return

+151.76%

Copying Kyle Mikson CFA's trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +151.76% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0A88 Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0A88 has received 12 Buy Ratings, 12 Hold Ratings, and 0 Sell Ratings. 0A88 average Analyst price target in the past 3 months is 50.36.

Each month's total comprises the sum of three months' worth of ratings.

0A88 Financial Forecast

0A88 Earnings Forecast

Next quarter’s earnings estimate for 0A88 is -$0.27 with a range of -$0.34 to -$0.20. The previous quarter’s EPS was -$0.14. 0A88 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0A88 has Performed in-line its overall industry.

0A88 Sales Forecast

Next quarter’s sales forecast for 0A88 is $147.21M with a range of $146.20M to $148.76M. The previous quarter’s sales results were $151.04M. 0A88 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0A88 has Performed in-line its overall industry.

0A88 Stock Forecast FAQ

What is GB:0A88’s average 12-month price target, according to analysts?

Based on analyst ratings, 10x Genomics Inc’s 12-month average price target is 50.36.

What is GB:0A88’s upside potential, based on the analysts’ average price target?

10x Genomics Inc has 9.70% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is 10x Genomics Inc a Buy, Sell or Hold?

10x Genomics Inc has a consensus rating of Moderate Buy, which is based on 6 buy ratings, 7 hold ratings and 0 sell ratings.

What is 10x Genomics Inc’s share price target?

The average share price target for 10x Genomics Inc is 50.36. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $65.00 ,and the lowest forecast is $40.00. The average share price target represents 9.70% Increase from the current price of $45.91.

What do analysts say about 10x Genomics Inc?

10x Genomics Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of 10x Genomics Inc?

To buy shares of GB:0A88, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

10x Genomics (0A88) Share Forecast & Price Target

0A88 Analyst Ratings

0A88 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering 10x Genomics

0A88 Analyst Recommendation Trends

0A88 Financial Forecast

0A88 Earnings Forecast

0A88 Sales Forecast

0A88 Stock Forecast FAQ

Detailed List of Analyst Forecasts